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Abstract Approximately one third of all colorectal malignancies are located in the rectum. It
has long been recognized that rectal cancers behave differently from colonic tumors, namely
in terms of local recurrence. For this reason, speciﬁc protocols have been developed to manage
this disease both in staging procedures as well as in neoadjuvant and adjuvant chemoradiation
treatments. Magnetic resonance imaging is now obligatory for rectal cancer staging. Also, pre-
operative chemoradiation is recommended in the large majority of locally advanced rectal
cancers with obvious advantages in downstaging and downsizing tumors, sometimes allowing
spincteric-sparing procedures. Total mesorectum excision is now the rule when operating on
rectal cancer. Despite these advances, there are still unanswered questions, namely the utility
of using neoadjuvant protocols in low lying, early stage tumors with the aim of performing a
local excision procedure and the utility of re-staging the disease after neo-adjuvant treatment.
In fact, response to neoadjuvant therapy may become a cornerstone of rectal cancer treat-
ment and individualized therapy. Finally, there is the concern that with current protocols, we
are overtreating some patients that would not need such extensive treatment.
In this review, we critically examine recent advances in staging, surgery, and chemoradiation
in the management of patients with rectal cancer which have not typically been incorporated in
published treatment guidelines.
© 2014 Sociedade Portuguesa de Gastrenterologia. Published by Elsevier España, S.L.U. All rights
reserved.
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PALAVRAS-CHAVE
Cancro do reto;
Tratamento
multimodal;
Terapêutica
individualizada
Manejo do cancro do reto: os tempos estão a mudar
Resumo Cerca de um terc¸o de todos os tumores coloretais estão localizados no reto. Desde
há longa data que é reconhecido que os tumores do reto têm um comportamento diferente dos
tumores do cólon, nomeadamente em termos de recidiva local. Por este motivo, foram desen-
volvidos protocolos especíﬁcos para manejar esta doenc¸a, tanto em termos de estadiamento
como em termos de tratamentos neoadjuvantes e adjuvantes. A ressonância magnética é agora
obrigatória como método de estadiamento. Por outro lado, a quimioradioterapia preoperatória
é recomendada na grande maioria das neoplasias localmente avanc¸adas com vantagens óbvias
no downstaging e downsizing dos tumores tratados, permitindo por vezes procedimentos cirúr-
gicos com conservac¸ão do aparelho esﬁncteriano. A excisão do mesoreto é a regra na cirurgia
destes tumores. Apesar destes avanc¸os, continuam a existir questões para as quais não existe
uma resposta clara, nomeadamente a utilizac¸ão de protocolos neoadjuvantes em tumores do
terc¸o inferior e precoces com o intuito de realizar uma ressec¸ão local bem como a utilidade
de re-estadiar estes tumores depois da terapêutica neo-adjuvante. De facto, a resposta à ter-
apêutica preoperatória poder-se-á tornar um fator decisivo na implementac¸ão de protocolos
de terapêutica individualizada. Finalmente, estudos recentes também levantam a questão de
alguns dos doentes selecionados para terapêutica neo-adjuvante estarem a ser sobretratados.
Na atual revisão, tentámos rever de forma crítica os avanc¸os recentes utilizados no esta-
diamento e tratamento destas neoplasias e que atualmente ainda não estão incorporados nas
recomendac¸ões publicadas.
© 2014 Sociedade Portuguesa de Gastrenterologia. Publicado por Elsevier España, S.L.U. Todos
os direitos reservados.
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increases the risk of compromised CRM (CRM+), which isIntroduction
Rectal cancers (RC) comprise approximately 25% of all
primary colorectal cancers and follow a different natu-
ral disease course compared to colonic tumors. It is well
established that surgical approach, local recurrence rates
and associated complications of early stage rectal tumors
are distinct from colonic cancers. This led to the estab-
lishment of speciﬁc and distinct protocols for staging and
treatment of RC, namely the use of magnetic resonance
imaging (MRI) for staging as well as the use of preoper-
ative chemoradiation in selected cases.1 These advances
in the management of patients with RC in the last decade
contributed to a marked improvement in patients’ out-
comes. In the United States ﬁve-year survival increased from
of 49.2% in the 70s’ to 68.5% in the 2000--2005 period. The
same trend was observed in Europe.1--3 This improvement
may be related not only to disease detection at an ear-
lier stage and widespread use of optimal surgery with total
mesorectal excision (TME) but also to a multidisciplinary
approach in specialized centers with an increased use of
both radiotherapy and chemotherapy, ideally in a neoadju-
vant context.3,4
Despite these advances, many issues remain unanswered,
namely whether the surgical approach after chemoradia-
tion can be modiﬁed based on tumor response, the wait and
watch strategy for complete responders and more recently,
whether preoperative radiotherapy should be selective,
probably based on MRI ﬁndings.
In this review, we will review recent changes in the mul-
timodal approach to this tumor.
b
i
iumor staging
re operative
reoperative staging of RC has two main objectives: to
eﬁne the pertinent anatomy for surgical planning and
o determine prognosis. Staging process begins with digital
ectal examination. The accuracy of T assessment by digi-
al examination ranges from 58% to 88%, largely depending
n the surgeon’s experience.5 For the precise localization
f tumors, especially those beyond the reach of an exam-
ning ﬁnger, rigid proctoscopy is obligatory and should be
onsidered as the single most useful tool.
In the initial preoperative setting, superﬁcial, RCs are
robably best staged by endoscopic ultrasonography (EUS),
hereas MRI should be used in all other RCs because
f its proven high sensitivity and speciﬁcity in deter-
ining N-stage, extramural vascular invasion (EMVI) and
ircumferential resection margin (CRM).6--8 EUS more accu-
ately determines T category as compared to MRI, although
ow-lying, very high or near-obstrutive tumors are major
rawbacks to the use of EUS. Both MRI and EUS share
he risk of understaging small lymph nodes (LN) especially
hen criteria to distinguish inﬂammatory from pathologic
N rely mainly on size, as many as 25% of positive LNs are
maller than 3mm.9 Although not included in TNM classi-
cation, tumor proximity to the mesorectal fascia (MRF)etter predicted by MRI and which has been shown to be an
ndependent risk factor of LR when determined by patholog-
cal examination.10 The MRF with tumor in close proximity
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Figure 1 Axial T2-weighted MRI images show rectal tumor.
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fistance between the tumor and mesorectal fascia (MRF) is less
han 1mm (white arrow) representing a threatened MRF.
1mm on MRI) has an increased risk of having a positive
RM as is therefore called a «threatened» MRF (Fig. 1).
ecently, the Mercury study was published with the aim of
ssessing the prognostic relevance of high resolution MRI
f CRM.11 The authors concluded that this staging was supe-
ior to AJCC TNM-based criteria for assessing both local
nd distant recurrence. Accordingly, treatment protocols
ncluding preoperative radiotherapy should probably con-
ider these ﬁndings. For systemic staging, CT scan of the
hest, abdomen, and pelvis is usually sufﬁcient. Thus, in
ractical terms, it is probably more cost-effective to per-
orm CT scan of the chest (which does not need contrast)
ombined with abdominal and pelvic MRI. Rectal EUS should
nly be ordered if pelvic MRI is inconclusive in distinguishing
2 vs. T3N0 tumors. PET-CT imaging cannot be recom-
ended routinely since it only changes patient management
n 15% of patients.12ost-treatment staging
s discussed below, tumors staged as T3 N+ or higher
re currently managed with neo-adjuvant (CRT). A new
w
m
a
c
igure 2 (A) High deﬁnition axial T1-weighted MRI post-Gd clearly
at. (B) Axial diffusion-weighted at the same level shows hyperintenM. Cravo et al.
oncept states that re-staging after CRT might help to iden-
ify complete responders and thereby modify treatment
nd/or surgical strategy.13 Although this might be debatable,
ost chemoradiation restaging is a challenge to all imaging
odalities due to radiation-induced changes, namely ﬁbro-
is, edema, inﬂammation, and necrosis. The optimal interval
etween CRT and surgery has not been clearly deﬁned.
he Lyon R90-01 study compares a period of less than two
eeks with six to eight weeks and found improved T and N
ownshift with longer intervals.14 In a recent review from
leveland Clinic, there was a steep increase in pathologic
omplete response (pCR) after 7 weeks which reached a
lateau only after twelve weeks.15 Therefore, an interval
f seven weeks after CRT but less than twelve weeks is now
ecommended for post CRT restaging. In respect to the most
ppropriate imaging, high deﬁnition MRI has been shown to
ccurately distinguish patients with post-treatment tumors
onﬁned to the muscularis propria or more superﬁcially (T0-
2N0), from those with more advanced tumors (Fig. 2).16
merging data suggest that reassessment using a combina-
ion of high-resolution MRI and diffusion-weighted imaging
DWI), may provide valuable prognostic information before
eﬁnitive surgery,17--21 as the latter may distinguish viable
umor from ﬁbrosis or inﬂammatory from neoplastic LN
Fig. 3).22
urgery
he main aim of surgical treatment of RC is to reduce the
isk of residual disease and local relapse while preserving
phincteric, urinary and sexual functions. There are a vari-
ty of surgical options in the treatment of RC, which depend
ot only on tumor location and stage but also on patient
phincter function. Sphincter preservation should not be
ttempted in those patients with incontinence unless the
phincter can be repaired.
These methods include local procedures, such as
ransanal local excision and transanal endoscopic micro-
urgery (TEM) and more invasive procedures involving
transabdominal resection (anterior resection -- AR)
ith colorectal anastomosis, proctectomy with total
esorectal excision (TME) and colo-anal anastomosis or
n abdominoperineal resection (APR) with a deﬁnitive
olostomy.
depicts rectal tumor, with transmural stranding in mesorectal
sity of the rectal wall involved by tumor.
Multimodal management of rectal cancer
Figure 3 After chemoradiation axial diffusion-weighted
shows hyperintensity of the node and rectal wall involved by
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recurrence and reduced survival. This difference in outcome
may be explained by the fact that tumors below the perit-tumor.
Local excision methods
Local excision methods are performed transanally with
a deep margin outside the muscularis propria into the
mesorectal fat and a mucosal margin with 1 cm or more
around the target lesion. These procedures are reserved for
selected cases with a low likelihood of nodal metastasis.
This probability depends on the depth of tumor invasion
(T stage), tumor differentiation and LVI. For tumors con-
ﬁned to the submucosa, associated nodal metastasis have
been reported in 6--11 percent of patients, while cancers
invading the muscularis propria have a 10--20 percent risk
of nodal metastases and this risk increases to 33--58 percent
in tumors extending into the perirectal fat.23 The incidence
of LN metastases also increases dramatically with grade of
tumor differentiation with up to 50% of poorly differentiated
tumors exhibiting lymph nodes metastasis.24
Early RC (conﬁned to the rectal wall without nodal
or distant disease -- T1N0M0 -- with no lymphovascular or
perineural invasion, well differentiated and mobile) can be
treated with local excision through the ‘‘Parks transanal
local excision’’ or transanal endoscopic microsurgery
(TEM).25 Parks transanal local excision is appropriate for
selected T1N0M0 early RC less than 3 cm in diameter, located
in the 8 cm distal rectum, and occupying less than 40% of the
circumference of the rectal wall. TEM is a minimally inva-
sive surgical technique originally described by Buess et al. in
the 80s’,26--28 which uses a transanal approach with a set of
endoscopic surgical instruments that can reach further into
the rectum (until 20 cm from the anal verge), along with a
form of enhanced or assisted vision.
Both techniques require a full thickness excision per-
formed perpendicularly through the bowel wall into the
perirectal fat, with negative (>3mm) deep and mucosal
margins, while avoiding fragmentation (Fig. 4).25 However,
anatomic considerations may prevent local excision even
if tumor staging is appropriate. In large lesions, full thick-
ness excision and primary closure can lead to loss of rectal
o
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olume and strictures, creating poor functional results par-
icularly if combined with pelvic radiation.
Local therapies are appealing because of their technical
ase, low complication rate, rapid post operative recov-
ry with minimal mortality and morbidity, and above all
ecause they avoid the need for a permanent stoma in
arly, distally located RCs.26 The major drawback to local
rocedures, include the absence of pathological staging of
odal involvement, mainly because there is evidence that LN
icrometastases also exist in early RC and are unlikely to be
dentiﬁed by endorectal ultrasound. If unfavorable features
re observed on pathological examination (high grade, posi-
ive or indeterminate margins, perineural or lymphovascular
nvasion) a radical excision is warranted.25
Although more controversial, T2 lesions can also be suc-
essfully treated with local excision, especially if combined
ith neo-adjuvant CRT, although long term outcomes are
nknown. The on-going study ACOSOG trial Z604129 which
s a single-arm study evaluating the oncologic outcome of
atients with T2N0M0 distal rectal cancers treated with CRT
ollowed by local excision, may shed some light on this
ssue. Moreover, the observation that a complete mucosal
esponse often corresponds to negative LNs, also sup-
orts the strategy of less aggressive surgical treatments in
atients submitted to CRT and with a complete clinical and
adiological response.13 Close follow-up after this strategy is
andatory.
adical resections
ocal recurrence is a major drawback of isolated loco-
egional treatments such as surgery. In the late 1970s, Heald
t al30 developed the technique of total mesorectal excision
TME) demonstrating that, in some cases, nests of tumor
ells outside lymph nodes could be found in the mesorec-
um and would be left behind by a ‘‘conventional’’ anterior
esection. Using TME alone, Heald et al.31 achieved local
ecurrence rates of less than 5% and emphasis became
ocused on the CRM.32--35 Over the last two decades, TME has
rought a dramatic improvement in the outcome of surgery
or rectal cancer. Anterior resection (AR) is indicated for
umors in the two proximal thirds of the rectum but can also
e performed in distal rectal tumors with no involvement
f the sphincter. In AR there should be a 5 cm oncological
argin from the distal end of the tumor for more prox-
mal tumors but 1--2 cm margins are acceptable for very
istal tumors, especially after neo-adjuvant CRT, thereby
llowing a sphincter-sparing procedure to be performed.
hen resection with safe margin carries the loss of conti-
ence (direct involvement of the sphincter or levators) or
hen preoperative continence function is already compro-
ised, an APR is indicated with a deﬁnitive colostomy.
lthough it has been the gold standard of distal rectal cancer
urgical therapy, it is nowadays performed in less than 5% of
ll cases.
Retrospective comparative studies of patients treated
ith AR and APR, revealed that APR has higher values of localneal reﬂection are usually at a higher stage and have a
ifferent lymphatic drainage which might not be included
196 M. Cravo et al.
Figure 4 TEM resection of a neoplastic lesion (T1N0) located 20 cm from the anal verge. (A) Delimitation of tumor margins.
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tB) Full thickness excision performed perpendicularly through
perative wound.
n the package of the TME, with higher incidence of lateral
elvic lymph node involvement.36
In the distal third of the rectum the mesorectum dis-
ppears at the top of the sphincter. Below this level, the
phincter constitutes the CRM. Distal rectal tumors have a
horter distance to cross until the CRM as compared to more
roximal tumors, ‘‘protected’’ by a thicker mesorectum.
ased on the study of the morphometry of the surgical speci-
en, West et al.37,38 demonstrated that APR specimens have
ess tissue volume around the tumor when compared with
R, which was associated with a greater CRM involvement,
ocal recurrence and less overall survival. This problem
ould be overcome with a ‘‘new’’ APR, introduced by Holm
t al.,39 more cylindrical and closer to the original Miles
escription, with removal of more tissue around the tumor,
educing the probability of CRM involvement.37,38 This oper-
tion involves an abdominal dissection with removal of the
ectum and mesorectum down to the levators and a wider
erineal dissection, in prone position, with removal of the
nal canal, levators and coccyx from below. The perineal
efect can be closed with ﬂaps.
ntersphincteric resection
umors below 5 cm from the anal verge were not usually
onsidered for a sphincter-sparing surgery because it was
ot possible to obtain a distal margin of 2 cm through a
onventional laparotomy. In this context, the intersphinc-
eric resection (ISR) was introduced as a form of treatment
or distal rectal tumors, considering that the mesorectum
erminates at the top of the sphincter complex.40
i
a
C
dbowel wall into the perirectal fat. (C) Final closure of the
ISR is indicated for well differentiated tumors located
elow 5 cm from the anal verge with predictably nega-
ive CRM in MRI. Involvement of the internal sphincter is
ot a contraindication. In contrast, ISR should not be per-
ormed in ﬁxed tumors, involving the external sphincter
r levators as well as in patients with poor preoperative
ontinence.38,40 Limitations for sphincter-sparing proce-
ures are beginning to be regarded as mostly functional and
ot just oncological.41,42
Despite laparoscopic approach of colon cancer is now
niversally accepted, the extension of this approach to RC
s still controversial. There is an evident lack of data and
he CLASICC study remains the only randomized controlled
ulticentre trial comparing the results of classic and laparo-
copic approach to rectal cancer surgery. Some groups still
xpress oncological concerns based on the ﬁrst results of this
tudy, which reported higher rates of CRM involvement and
trend for worst sexual male function in the laparoscopic
roup. These results were not reproduced and at 3 and
years there are no signiﬁcant differences between both
pproaches,43--45 thereby encouraging the use laparoscopic
pproach in RC.46
hemoradiation treatment
revious studies have consistently shown that postopera-
ive 5-ﬂuorouracil (5FU)-based chemoradiation signiﬁcantly
mproves local control and survival compared with surgery
lone.47--49 When radiotherapy was compared to concurrent
RT, the German Rectal Cancer Trial50 conﬁrmed that CRT
elivered preoperatively, results in a signiﬁcant decrease
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in acute and late toxicities, concomitantly with a better
local control of disease and a higher chance of sphincter
preservation. Since then, the standard treatment for locally
advanced, clinically resectable (T3 and/or N+) rectal cancer
is preoperative CRT.
Although 5-ﬂuorouracil continuous infusion (5FU-CI) is
the conventional regimen used,47--49 two recently published
studies showed that capecitabine has similar rates of pCR,
sphincter-sparing surgery, and toxicity,51,52 and so both
agents can be used in the neo-adjuvant setting.
In patients with pretreatment stage I disease (T2N0),
neoadjuvant CRT therapy may be considered in distally
located tumors with the aim of downsizing, thereby increas-
ing the chances of a sphincter sparing procedure53,54;
however the beneﬁts of this strategy remains unproven.
Preoperative vs. postoperative
chemoradiation
Two randomized trials compared preoperative vs. post-
operative chemoradiation for clinically resectable rectal
cancer. The German trial55 completed the planned accrual
of more than 800 patients with rectal cancers less than
16 cm from the anal verge who were randomized to preop-
erative CRT vs. postoperative CRT. Patients who received
preoperative therapy had a signiﬁcant decrease in local
recurrence (6% vs. 15%; P = .006), acute toxicity (27% vs. 40%;
P = .001), and chronic toxicity (14% vs. 24%; P = .012) when
compared with postoperative therapy. In addition, there
was a signiﬁcant increase in sphincter preservation surger-
ies (39% vs. 20%; P = .004). No differences were observed
in 5-year survival. At 10 years the local control beneﬁt of
preoperative vs. postoperative therapy was still observed.
In contrast to these results which clearly favorable to pre-
operative treatment, in the NSABP R-03 trial56 this beneﬁt
was not as obvious. However, the results of the NSABP trial
should be interpreted with caution because only 267 of the
900 planned patients were accrued, limiting the statistical
power to detect differences. Based on these results, preop-
erative chemoradiation remains the standard of care.
Short-course radiotherapy vs. long-course
chemoradiation
The two main strategies of preoperative radiotherapy are
long-course chemoradiation and short-course radiation. The
ﬁrst, involves the delivery of a long course of preoperative
radiotherapy using conventional doses of 1.8--2Gy per frac-
tion over 5--6 weeks, with a total dose of 45--50.4Gy. This
approach typically involves the administration of concurrent
5FU or capecitabine-based chemotherapy and is the most
accepted approach worldwide.52
The rationale for giving chemotherapy concurrently with
radiotherapy is that it potentiates local radiotherapy sensi-
tization and has the potential to induce tumor downsizing
and/or downstaging, hopefully improving rates of sphinc-
ter sparing procedures and increasing rates of pathological
complete response (pCR).36 The second, traditionally used
in Scandinavia, consists of short-course preoperative radio-
therapy (SCPRT) delivering a total dose of 25Gy over 5 days
(5 fractions) without chemotherapy, followed by surgery
5
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ithin 10 days of the ﬁrst session of radiotherapy.57--59 The
ationale for this regimen is that the short time period for
elivery of the dose may counteract the effects of acceler-
ted cellular repopulation, a phenomenon characteristic of
umor cells exposed to radiotherapy.
In patients with T3/4 rectal cancer, the delivery of a
ong course of preoperative radiotherapy concurrent with
hemotherapy is associated with a relative risk reduction
n local recurrence of approximately 50%, whereas short-
ourse radiotherapy does not result in apparent downstaging
f tumors in terms of nodal status.58
Two large RCT studied the effect of SCPRT in both local
ecurrence and 5-year survival.57,58 Although the results of
oth of these trials favor SCPRT, both were performed before
he widespread introduction of TME surgery and, therefore,
t remains to be proven whether this beneﬁcial effect would
lso be observed if TME had been performed.
Therefore on the basis of available evidence, long-
ourse chemoradiation appears preferable, particularly for
atients with distal tumors or threatened margins.
hange of surgical strategy based
n post-treatment staging
estaging after neo-adjuvant CRT might help to identify
esponders to therapy in whom planned treatment based
n the original presentation might no longer be indicated.
s discussed earlier, the post-treatment assessment often
nables sphincter preservation due to tumor downsizing
nd T or N downshifting.13 A natural assumption would be
hat tumors initially staged as T3N0 who after CRT had a
ownshilt to T0/T1N0 could be safely managed by local
xcision. Further supporting this practice, in the German
ectal Cancer Study Group,48--50 the surgeons’ pretreatment
urgical recommendation was compared with the surgi-
al procedure after neo-adjuvant CRT. Forty percent of
atients originally thought to need APR actually under-
ent a sphincter-preserving procedure without oncologic
ompromise at a median follow-up of 45 months. However,
here are no prospective clinical trials supporting this strat-
gy. The on-going ACOSOG trial Z6041 which is a single-arm
tudy evaluating the outcome of patients with T2N0M0 distal
C treated with CRT followed by local excision procedures,
ill certainly help to clarify this issue.29
CRT causes tumor necrosis, which is then replaced by
nﬂammatory tissue and ultimately ﬁbrosis. Pathologists can
uantify the ratio of viable tumor cells to ﬁbrosis to gener-
te a tumor regression grade (TRG).60 In regard to lymph
ode response to CRT the only accurate method is patho-
ogic examination of the surgical specimen, but previous
bservations strongly support the hypothesis that there is
close relationship between primary tumor post-treatment
stage and risk of persistent lymph node metastasis.61
or this reason, Kosinsky et al.13 consider that mucosal
esponse can be viewed as a proxy for LN response. Using
taging and neoadjuvant CRT protocols discussed above,
e may expect rates of pathologic response ranging from
% to 42%.62 For this reason, some authors now propose
new algorithm in which surgical approach is based on
esponse to neoadjuvant treatment.13 Although not vali-
ated, it provides a framework for the incorporation of
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reatment response in operative planning and sets the stage
or considering less radical operative strategies or even
wait and watch strategy in which highly selected RCs
re not operated immediately.13 This strategy is really a
no-immediate» surgical approach, recommended only in
ighly selected patients who require intensive follow-up
ith rectal and endoscopic examinations, especially during
he ﬁrst year. Full excisional biopsy is performed in equivocal
ases. Disease recurrence in patients previously identiﬁed as
aving had a complete clinical response, requires surgical
alvage which has been shown not to compromise outcome
s compared with patients who received immediate surgery
fter neoadjuvant CRT.63
ostoperative adjuvant chemotherapy after
eoadjuvant chemoradiation and surgery
he neoadjuvant CRT approach commits patients to the
ntire three component package of CRT, surgery and adju-
ant therapy. Beets et al.53 performed a pooled analysis
f 2724 patients who received preoperative chemoradia-
ion. Overall, 41% received postoperative chemotherapy and
here was no beneﬁt in disease-free survival in the sub-
et of patients with ypT0N0 or ypT3-4Nx disease. Patients
ith ypT1-2N0 disease had the greatest beneﬁt, proba-
ly because patients who were responders to CRT were
lso selected. Thus, although its beneﬁt remains contro-
ersial, most investigators feel that it is reasonable to
se the same adjuvant chemotherapy for colon cancer.54
or patients selected to receive postoperative adjuvant
hemotherapy, 4 months (8 cycles) of FOLFOX/CAPOX or
apecitabine monotherapy is recommended although car-
ying the risk of potentially overtreating some patients.
ovel approaches to neo-adjuvant treatment
- the PROSPECT study
s stated before, contemporary management of locally
dvanced rectal cancer involves preoperative chemoradi-
tion, followed by surgery and then adjuvant systemic
hemotherapy. However, although before the advent of TME,
R was a major problem, nowadays the vast majority of rec-
al cancer deaths are from disseminated metastatic disease,
hich reinforces the importance of systemic treatment.64
he problem with the current strategy is that neoadjuvant
RT utilizes either 5-ﬂuorouracil or capecitabine solely as
ensitizing agents. Effective chemotherapy with FOLFOX or
APOX will only start 20--24 weeks from diagnosis, allow-
ng for possible dissemination of micrometastases. As a
esult, the Alliance for Clinical Trials in Oncology launched
he PROSPECT trial early in 2012 -- Preoperative Radiation
r Selective Preoperative radiation and Evaluation before
hemotherapy and TME,65 with the aim of moving systemic
herapy more proximally in the total treatment course. It is a
hase II/III randomized trial to evaluate the impact of selec-
ive use of radiation in the era of TME and high-quality MRI
maging. Therefore, in the intervention arm, patients would
rst start with systemic treatment (FOLFOX× 6 cycles) with
estaging of primary tumor after that. If any progression
as observed or regression was lower than 20%, the classic
RT protocol would be performed. If not, the patient would
C
TM. Cravo et al.
roceed immediately to low anterior resection with TME,
ventually followed by an additional 6 cycles. Patients with
nexpected positive surgical margins would receive postop-
rative radiation. This novel approach incorporate selective
ather than consistent use of radiation in the treatment
f mid RC and customizes subsequent treatment based on
esponse to neoadjuvant FOLFOX.
onclusions
ultimodal treatment of RCwith preoperative CRT in clinical
3N1 cases has improved local recurrence rates and, in the
ome cases, has allowed a sphincter preservation procedure.
ME is now part of an optimal radical resection for RC with
he emphasis on CRM.
However, recent studies start to question this classic
pproach because of a number of issues. First, there is clear
vidence that pathologic stage after neo-adjuvant CRT more
ccurately indicates prognosis than initial clinical stage.
owever, NCCN and ESMO treatment guidelines, besides
ot recommending restaging after neoadjuvant therapy, still
onsider cTNM staging as an indicator for such therapy
hereas recent studies demonstrate that high deﬁnition MRI
ith accurate staging of CRM, may be a better predictor
or both local and distant recurrence. Also, preoperative
RT might also be considered in patients with T2N0 distally
ocated tumors and, in very carefully selected responders,
wait and watch strategy may be recommended. Finally,
here are now concerns that by submitting to CRT all patients
linically staged as T3N+, we might be (i) overtreating some
atients (ii) delaying systemic treatment to 4--5 months
fter diagnosis thereby increasing the risk to systemic dis-
emination.
Therefore, management of RC is clearly going to
hange in a near future and it is of paramount impor-
ance that these patients are referred to specialized centers
here these multiple and possible strategies are extensively
iscussed in a multidisciplinary team. Gastroenterologists
hould deﬁnitely be part of this team!
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